Share

    


Home / Search Results

Search Results

You searched for:

ACCCBuzz spoke with Luis E. Raez, MD, FACP, FCCP, to learn more about the importance of closing the gap in access to biomarker testing and strategies to improve equity and inclusion in precision medicine.
With the variety of models and titles that have emerged under precision medicine stewardship, learn how one cancer program is breaking down the this complex landscape into streamlined workflows to improve efficiency and better support growing test volumes.
Introduced in 2021, the Cancer Patient Equity Act seeks to provide coverage of certain cancer diagnostic and laboratory tests under Medicare, Medicaid, and the Children's Health Insurance Program, and more.
Care optimization is everything in today’s rapidly changing healthcare landscape. Learn how ACCC's nationwide quality improvement (QI) initiative helped Southern Ohio Medical Center Cancer Center develop and implement plans to support the optimization of care for patients diagnosed with Stages III and IV non-small cell lung cancer (NSCLC).
Cancer programs and practices can leverage technology to mitigate the impact of social determinants of health (SDOH). Learn about three companies and their technology that is developed to advance equity in cancer care delivery.
Communities around the globe recognize August 1 as World Lung Cancer Day—a day to commemorate, educate, and support individuals and families impacted by lung cancer. Read highlights on a few ACCC initiatives that are helping cancer care teams better support their patients with this disease.
To fill a care gap, The James Cancer Hospital opened a new set of front doors to its facility—The James Cancer Diagnostic Center—to ensure all patients with a concern for cancer could be quickly evaluated, even if they didn’t have a confirmed diagnosis.
Measurable residual disease (MRD) has gained traction as a compelling marker for disease status across various hematologic malignancies, including multiple myeloma. Learn how MRD is uniquely suited to help evaluate the depth of treatment response.
With data already demonstrating the role of MRD for CLL response assessment and prognosis, cancer programs should prepare themselves for implementation of MRD testing for appropriate patients.
The second post in a three-blog series, ACCCBuzz shares how Carolina Blood and Cancer Care Associates' NOLA initiative is addressing access to care, clinical trials, biomarker testing, and more.
March is Multiple Myeloma Awareness Month. Learn how ACCC is supporting collaboration among healthcare providers with practical, scalable solutions to the real-world challenges of improving quality care delivery for patients with multiple myeloma.
In 2021, ACCC held a series of focus groups to learn how cancer programs are effectively implementing telehealth to manage symptoms and treatment side effects, deliver psychosocial screening and support services, and provide genetic counseling and testing.
As precision medicine becomes more common in the management of lung cancer, little is understood about the patient experience with biomarker testing, particularly of underserved patients. This study used survey and focus group methodology to determine patient perspectives on the educational needs within this community.
An expert ACCC Steering Committee shares 32 informed treatment and care delivery recommendations for the ideal care of patients with non-small cell lung cancer.
An integrated precision tracking program ensures proper follow-up care and surveillance for survivors of colorectal cancer.
This ACCC education program shares key highlights from a national survey of thoracic surgeons, radiation oncologists, and medical oncologists on the barriers that exist in the ideal management of patients with NSCLC.